By Dr Chris Haqq (Elicio Therapeutics)2024-07-18T10:00:01
In this exclusive interview with Elicio Therapeutics, we explore the transformative potential of liquid biopsy in oncology drug development, particularly spotlighting its application in Elicio’s AMPLIFY-201 study of ELI-002, a promising therapeutic cancer vaccine candidate.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-07-08T12:00:00Z
2026-07-08T09:00:00Z
2024-02-01T12:06:43
Sponsored by Leica Microsystems
2023-12-11T10:49:07
Sponsored by Leica Microsystems
2025-11-13T14:00:00
Sponsored by Cell Signaling Technology
2026-06-15T11:00:00
Sponsored by Miltenyi Biotec
2024-01-10T08:56:17
Sponsored by Leica Microsystems
2025-10-22T14:00:00
Sponsored by Wuxi Biologics
Site powered by Webvision Cloud